Alunbrig
May 02, 2017
FDA Approves; AZ nabs; Nordisk settles; Novartis pays
FDA Approves Alunbrig (brigatinib) for Rare Lung Cancer Takeda Pharmaceuticals announced the FDA approved Alunbrig (brigatinib) to treat patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Brigatinib is a kinas...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
